BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

160 related articles for article (PubMed ID: 20031821)

  • 1. Paclitaxel versus sirolimus stents in diabetic and nondiabetic patients.
    Chiu M; Ko DT; Austin PC; Cohen EA; Velianou JL; Goeree R; Blackhouse G; Tu JV
    Circ Cardiovasc Qual Outcomes; 2009 Mar; 2(2):96-107. PubMed ID: 20031821
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Differential clinical responses to everolimus-eluting and Paclitaxel-eluting coronary stents in patients with and without diabetes mellitus.
    Stone GW; Kedhi E; Kereiakes DJ; Parise H; Fahy M; Serruys PW; Smits PC
    Circulation; 2011 Aug; 124(8):893-900. PubMed ID: 21824922
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Paclitaxel- versus sirolimus-eluting stents for unprotected left main coronary artery disease.
    Mehilli J; Kastrati A; Byrne RA; Bruskina O; Iijima R; Schulz S; Pache J; Seyfarth M; Massberg S; Laugwitz KL; Dirschinger J; Schömig A;
    J Am Coll Cardiol; 2009 May; 53(19):1760-8. PubMed ID: 19422982
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Long-term clinical outcomes of sirolimus- versus paclitaxel-eluting stents for patients with unprotected left main coronary artery disease: analysis of the MAIN-COMPARE (revascularization for unprotected left main coronary artery stenosis: comparison of percutaneous coronary angioplasty versus surgical revascularization) registry.
    Lee JY; Park DW; Yun SC; Lee SW; Kim YH; Lee CW; Hong MK; Park SW; Park SJ
    J Am Coll Cardiol; 2009 Aug; 54(9):853-9. PubMed ID: 19695467
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Diabetic and nondiabetic patients with left main and/or 3-vessel coronary artery disease: comparison of outcomes with cardiac surgery and paclitaxel-eluting stents.
    Banning AP; Westaby S; Morice MC; Kappetein AP; Mohr FW; Berti S; Glauber M; Kellett MA; Kramer RS; Leadley K; Dawkins KD; Serruys PW
    J Am Coll Cardiol; 2010 Mar; 55(11):1067-75. PubMed ID: 20079596
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Two-year clinical outcomes with drug-eluting stents for diabetic patients with de novo coronary lesions: results from a real-world multicenter registry.
    Ortolani P; Balducelli M; Marzaroli P; Piovaccari G; Menozzi A; Guiducci V; Sangiorgio P; Tarantino F; Geraci G; Castriota F; Tondi S; Saia F; Cooke RM; Guastaroba P; Grilli R; Marzocchi A; Maresta A
    Circulation; 2008 Feb; 117(7):923-30. PubMed ID: 18250265
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Long-term paclitaxel-eluting stent outcomes in elderly patients.
    Forman DE; Cox DA; Ellis SG; Lasala JM; Ormiston JA; Stone GW; Turco MA; Wei JY; Joshi AA; Dawkins KD; Baim DS
    Circ Cardiovasc Interv; 2009 Jun; 2(3):178-87. PubMed ID: 20031714
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effectiveness and safety of drug-eluting stents in Ontario.
    Tu JV; Bowen J; Chiu M; Ko DT; Austin PC; He Y; Hopkins R; Tarride JE; Blackhouse G; Lazzam C; Cohen EA; Goeree R
    N Engl J Med; 2007 Oct; 357(14):1393-402. PubMed ID: 17914040
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Clinical outcomes after sirolimus-eluting, paclitaxel-eluting, and bare metal stents (from the first phase of the prospective multicenter German DES.DE Registry).
    Nienaber CA; Akin I; Schneider S; Senges J; Fetsch T; Tebbe U; Willich SN; Stumpf J; Sabin GV; Silber S; Richardt G; Kuck KH;
    Am J Cardiol; 2009 Nov; 104(10):1362-9. PubMed ID: 19892051
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical efficacy of drug-eluting stents in diabetic patients: a meta-analysis.
    Mahmud E; Bromberg-Marin G; Palakodeti V; Ang L; Creanga D; Demaria AN
    J Am Coll Cardiol; 2008 Jun; 51(25):2385-95. PubMed ID: 18565394
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risk factors for stent thrombosis after implantation of sirolimus-eluting stents in diabetic and nondiabetic patients: the EVASTENT Matched-Cohort Registry.
    Machecourt J; Danchin N; Lablanche JM; Fauvel JM; Bonnet JL; Marliere S; Foote A; Quesada JL; Eltchaninoff H; Vanzetto G;
    J Am Coll Cardiol; 2007 Aug; 50(6):501-8. PubMed ID: 17678732
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Comparison of 2-year clinical outcomes with sirolimus and paclitaxel-eluting stents for patients with diabetes: results of the Registro Regionale AngiopLastiche Emilia-Romagna Registry.
    Balducelli M; Ortolani P; Marzaroli P; Piovaccari G; Menozzi A; Manari A; Sangiorgio P; Tarantino F; Rossi R; Maresta A; Tondi S; Passerini F; Guastaroba P; Grilli R; Marzocchi A
    Catheter Cardiovasc Interv; 2010 Feb; 75(3):327-34. PubMed ID: 19937776
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Complete versus incomplete revascularization in patients with multivessel disease undergoing percutaneous coronary intervention with drug-eluting stents.
    Tamburino C; Angiolillo DJ; Capranzano P; Dimopoulos K; La Manna A; Barbagallo R; Tagliareni F; Mangiafico S; Guzman LA; Galassi AR; Bass TA
    Catheter Cardiovasc Interv; 2008 Oct; 72(4):448-56. PubMed ID: 18814218
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Paclitaxel-eluting coronary stents in patients with diabetes mellitus: pooled analysis from 5 randomized trials.
    Kirtane AJ; Ellis SG; Dawkins KD; Colombo A; Grube E; Popma JJ; Fahy M; Leon MB; Moses JW; Mehran R; Stone GW
    J Am Coll Cardiol; 2008 Feb; 51(7):708-15. PubMed ID: 18279734
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Randomized comparison of everolimus-eluting and paclitaxel-eluting stents: two-year clinical follow-up from the Clinical Evaluation of the Xience V Everolimus Eluting Coronary Stent System in the Treatment of Patients with de novo Native Coronary Artery Lesions (SPIRIT) III trial.
    Stone GW; Midei M; Newman W; Sanz M; Hermiller JB; Williams J; Farhat N; Caputo R; Xenopoulos N; Applegate R; Gordon P; White RM; Sudhir K; Cutlip DE; Petersen JL;
    Circulation; 2009 Feb; 119(5):680-6. PubMed ID: 19171853
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Outcome in the real-world of coronary high-risk intervention with drug-eluting stents (ORCHID) -- a single-center study comparing Cypher sirolimus-eluting with Taxus paclitaxel-eluting stents.
    Kumar S; Suresh V; Prendergast BD; Brooks NH; Wicks P; Levy RD; Ray SG; Bennett DH; Lee HS
    Catheter Cardiovasc Interv; 2006 Nov; 68(5):663-8. PubMed ID: 17034063
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical outcomes following percutaneous coronary intervention with drug-eluting vs. bare-metal stents in dialysis patients.
    Halkin A; Selzer F; Marroquin O; Laskey W; Detre K; Cohen H
    J Invasive Cardiol; 2006 Dec; 18(12):577-83. PubMed ID: 17197706
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The efficacy of sirolimus-eluting stents versus bare metal stents for diabetic patients undergoing elective percutaneous coronary intervention.
    Aoki J; Ong A; Rodriguez-Granillo G; VanMieghem C; Daemen J; Sonnenschein K; McFadden E; Sianos G; van der Giessen W; de Feyter P; van Domburg R; Serruys P
    J Invasive Cardiol; 2005 Jul; 17(7):344-8. PubMed ID: 16003016
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Impact of three or more sirolimus-eluting stents versus paclitaxel-eluting stents on clinical outcomes in patients undergoing percutaneous coronary intervention.
    Chu WW; Kuchulakanti PK; Torguson R; Wang B; Clavijo LC; Suddath WO; Pichard AD; Satler LF; Kent KM; Waksman R
    Catheter Cardiovasc Interv; 2006 Jul; 68(1):62-6. PubMed ID: 16755592
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Differences in restenosis rate with different drug-eluting stents in patients with and without diabetes mellitus: a report from the SCAAR (Swedish Angiography and Angioplasty Registry).
    Fröbert O; Lagerqvist B; Carlsson J; Lindbäck J; Stenestrand U; James SK
    J Am Coll Cardiol; 2009 May; 53(18):1660-7. PubMed ID: 19406341
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.